Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries SHAREHOLDER ALERT: BZ DIDI SESN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines By: The Law Offices of Vincent Wong via AccessWire August 23, 2021 at 10:45 AM EDT NEW YORK, NY / ACCESSWIRE / August 23, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.Kanzhun Limited (NASDAQ:BZ)If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/kanzhun-limited-loss-submission-form?prid=18830&wire=1Lead Plaintiff Deadline: September 10, 2021Class Period: June 11, 2021 - July 2, 2021Allegations against BZ include that: (1) Kanzhun would face an imminent cybersecurity review by the Cyberspace Administration of China ("CAC"); (2) the CAC would require Kanzhun to suspend new user registration on its BOSS Zhipin app; (3) Kanzhun needed to "to conduct a comprehensive examination of cybersecurity risks"; (4) Kanzhun needed to "enhance its cybersecurity awareness and technology capabilities"; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.Didi Global Inc. F/K/A Xiaoju Kuaizhi Inc. (NYSE:DIDI)If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/didi-global-inc-f-k-a-xiaoju-kuaizhi-inc-loss-submission-form?prid=18830&wire=1Lead Plaintiff Deadline: September 7, 2021This lawsuit is on behalf of persons and entities that purchased or otherwise acquired DiDi: (a) American Depositary Shares pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's June 2021 initial public offering; and/or (b) securities between June 30, 2021 and July 21, 2021, inclusive.Allegations against DIDI include that: (1) DiDi's apps did not comply with applicable laws and regulations governing privacy protection and the collection of personal information; (2) as a result, the Company was reasonably likely to incur scrutiny from the Cyberspace Administration of China; (3) the CAC had already warned DiDi to delay its IPO to conduct a self-examination of its network security; (4) as a result of the foregoing, DiDi's apps were reasonably likely to be taken down from app stores in China, which would have an adverse effect on its financial results and operations; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.Sesen Bio, Inc. (NASDAQ:SESN)If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=18830&wire=1Lead Plaintiff Deadline: October 18, 2021Class Period: December 21, 2020 - August 17, 2021Allegations against SESN include that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:Vincent Wong, Esq.39 East BroadwaySuite 304New York, NY 10002Tel. 212.425.1140Fax. 866.699.3880E-Mail: vw@wongesq.comSOURCE: The Law Offices of Vincent WongView source version on accesswire.com: https://www.accesswire.com/660911/SHAREHOLDER-ALERT-BZ-DIDI-SESN-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
SHAREHOLDER ALERT: BZ DIDI SESN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines By: The Law Offices of Vincent Wong via AccessWire August 23, 2021 at 10:45 AM EDT NEW YORK, NY / ACCESSWIRE / August 23, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.Kanzhun Limited (NASDAQ:BZ)If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/kanzhun-limited-loss-submission-form?prid=18830&wire=1Lead Plaintiff Deadline: September 10, 2021Class Period: June 11, 2021 - July 2, 2021Allegations against BZ include that: (1) Kanzhun would face an imminent cybersecurity review by the Cyberspace Administration of China ("CAC"); (2) the CAC would require Kanzhun to suspend new user registration on its BOSS Zhipin app; (3) Kanzhun needed to "to conduct a comprehensive examination of cybersecurity risks"; (4) Kanzhun needed to "enhance its cybersecurity awareness and technology capabilities"; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.Didi Global Inc. F/K/A Xiaoju Kuaizhi Inc. (NYSE:DIDI)If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/didi-global-inc-f-k-a-xiaoju-kuaizhi-inc-loss-submission-form?prid=18830&wire=1Lead Plaintiff Deadline: September 7, 2021This lawsuit is on behalf of persons and entities that purchased or otherwise acquired DiDi: (a) American Depositary Shares pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's June 2021 initial public offering; and/or (b) securities between June 30, 2021 and July 21, 2021, inclusive.Allegations against DIDI include that: (1) DiDi's apps did not comply with applicable laws and regulations governing privacy protection and the collection of personal information; (2) as a result, the Company was reasonably likely to incur scrutiny from the Cyberspace Administration of China; (3) the CAC had already warned DiDi to delay its IPO to conduct a self-examination of its network security; (4) as a result of the foregoing, DiDi's apps were reasonably likely to be taken down from app stores in China, which would have an adverse effect on its financial results and operations; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.Sesen Bio, Inc. (NASDAQ:SESN)If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=18830&wire=1Lead Plaintiff Deadline: October 18, 2021Class Period: December 21, 2020 - August 17, 2021Allegations against SESN include that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:Vincent Wong, Esq.39 East BroadwaySuite 304New York, NY 10002Tel. 212.425.1140Fax. 866.699.3880E-Mail: vw@wongesq.comSOURCE: The Law Offices of Vincent WongView source version on accesswire.com: https://www.accesswire.com/660911/SHAREHOLDER-ALERT-BZ-DIDI-SESN-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines